Bringing the Oncology Community Together

Dr. Pardee on CPI-613 in Hematologic Malignancies

Timothy S. Pardee, MD
Published Online: Wednesday, July 10, 2013
Timothy S. Pardee, MD, Assistant Professor, Hematology & Oncology, Wake Forest University Baptist Medical Center, describes a phase I trial looking at the first-in-class mitochondrial metabolism inhibitor CPI-613 in patients with advanced hematologic malignancies.

This drug is a small molecular inhibitor of a mitochondrial enzyme called pyruvate dehydrogenase complex. While normal cells use mitochondria as a means to efficiently generate energy, cancer cells use mitochondria to generate building blocks for more cancer cells. Because of that difference, Pardee says, researchers hypothesized that there would be a therapeutic wind to target cancer cells more specifically.

Through a collaboration with Cornerstone Pharmaceuticals, researchers tested CPI-613 in a phase I trial. The trial was design to determine the safest dose, toxicities, and activity in patients with relapsed/refractory hematologic malignancies. To their delight, Pardee says, researchers observed several dramatic responses.

Related Articles
Treatment of MDS Refractory to Hypomethylating Agent
Panelists discuss the limited number of treatment options that exist for patients with myelodysplastic syndromes who progress on hypomethylating agents, such as azacitidine and decitabine.
New MRD Assay Helps Move Testing Forward in Multiple Myeloma Research
An improved assay for assessing MRD status in patients with multiple myeloma is contributing to the momentum for using MRD as a surrogate endpoint for survival in clinical trials and as a tool with the potential to help guide therapy choices.
FDA Approves First-Line Ofatumumab for Fludarabine-Ineligble Patients With CLL
The FDA has approved ofatumumab plus chlorambucil for previously untreated patients with chronic lymphocytic leukemia who are considered inappropriate for treatment with fludarabine therapy.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.